[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Tiantan Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":602},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,242,0,25,[9,43,73,92,120,149,174,200,225,250,270,289,315,330,348,375,396,413,435,466,483,511,533,553,574],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100619225","dexamethasone-palmitate-for-postoperative-pain-100619225",false,"NCT07341854","Dexamethasone Palmitate for Postoperative Pain","Effect of Intravenous Dexamethasone Palmitate on Postoperative Pain Prevention","Inclusion Criteria:\n\n1. Age 18-65 years.\n2. Scheduled for a range of surgeries under general anesthesia, including both minimally invasive procedures (such as video-assisted thoracoscopic surgery and laparoscopy) and open surgeries (such as thoracotomy, laparotomy, spinal surgery, total joint replacement, and mastectomy).\n3. Capacity to comprehend the study procedures and assessment scales, and communicate effectively with research staff.\n\n4）Classified as American Society of Anesthesiologists (ASA) physical status I, II, or III.\n\n5\\) Willingness to participate voluntarily and provide written informed consent.\n\nExclusion Criteria:\n\n1. Known hypersensitivity to dexamethasone or its excipients.\n2. Systemic glucocorticoid therapy within 3 months prior to enrolment.\n3. History of severe cardiovascular disease, hepatic or renal failure, or systemic rheumatic disease (e.g., rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus).\n4. Coexisting chronic pain at enrolment.\n5. Uncontrolled diabetes mellitus or active systemic infection.\n6. Use of any systemic or topical analgesics within 48 hours prior to surgery.\n7. Significant cognitive impairment or severe psychiatric disorder.\n8. Pregnancy or lactation.","ALL","18 Years","65 Years",{"count":21,"type":22},446,"ESTIMATED","INTERVENTIONAL",[25],"NA","Postoperative pain remains highly prevalent and inadequately managed in a significant proportion of surgical patients, often leading to delayed recovery, increased opioid consumption, and potential progression to chronic pain. While perioperative systemic dexamethasone is used for its anti-inflammatory and opioid-sparing effects, its efficacy is inconsistent, and concerns regarding systemic side effects persist. Dexamethasone palmitate, a novel lipophilic prodrug formulated as nanoparticle emulsion, leverages the enhanced permeability and retention effect to target inflammatory sites selectively, potentially offering superior anti-inflammatory and analgesic efficacy with reduced systemic exposure. This trial aims to evaluate whether preoperative intravenous dexamethasone palmitate is more effective than conventional dexamethasone in preventing moderate-to-severe postoperative pain.",[28,29],"Pain, Postoperative","Dexamethasone Palmitate","RECRUITING","2026-08-17",{"date":33,"type":34},"2026-08-19","ACTUAL",{"date":36,"type":34},"2026-04-06",{"date":38,"type":22},"2027-12-30",{"name":40,"class":41},"Beijing Tiantan Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":72,"locationsCount":42},"100642716","phase-2-a-phase-2b-trial-of-lesion-network-mapping-guided-ctbs-for-motor-recovery-after-acute-ischemic-stroke-100642716","NCT07645560","A Phase 2b Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After Acute Ischemic Stroke","Lesion Network Mapping-Navigated Continuous Theta-Burst Stimulation for Motor Recovery in Acute Ischemic Stroke: A Randomized, Double-Blind, Sham-Controlled, Multicentre Phase 2b Trial: MASTRE-2","MASTRE-2","Inclusion Criteria:\n\n1. Age 18-80 years.\n2. Ischemic stroke onset within the past 14 days.\n3. Unilateral, supratentorial ischemic stroke confirmed by CT or MRI.\n4. Pre-stroke modified Rankin Scale (mRS) score of 0-1.\n5. NIH Stroke Scale (NIHSS) total score 6-25, with item 1a ≤ 1 point, and at least one of items 5a, 5b, 6a, or 6b ≥ 2 points.\n6. Written informed consent signed by the patient or the patient's legally authorized representative.\n\nExclusion Criteria:\n\n1. Contraindications to TMS (e.g. cranial metallic foreign bodies, cardiac pacemaker, implanted drug pump, cochlear implant).\n2. History of epilepsy or seizure, intracranial hypertension, tumor, or other serious neurological disease.\n3. Midline shift or parenchymal mass effect on cranial CT or other imaging.\n4. CT or MRI evidence of bilateral acute cerebral infarction or infratentorial acute infarction (brainstem or cerebellum).\n5. Evidence of acute intracranial hemorrhage, including spontaneous intracerebral hemorrhage, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage.\n6. Pre-stroke mRS ≥ 2.\n7. Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg despite antihypertensive treatment.\n8. Pregnant or breastfeeding women, or women planning pregnancy within 90 days.\n9. Severe psychiatric disorders or dementia (or other conditions) precluding informed consent or follow-up.\n10. Concomitant malignant tumor or severe systemic disease with life expectancy \\\u003C 90 days.\n11. Participation in any other interventional clinical study within 30 days before randomization, or currently enrolled in such a study.","80 Years",{"count":53,"type":22},60,[55],"PHASE2","This Phase 2b study will evaluate whether lesion network mapping-guided continuous theta burst stimulation (cTBS) can improve recovery after acute ischemic stroke. The treatment uses each participant's brain imaging to identify individualized stimulation targets related to stroke symptoms. Participants will receive either active cTBS or a sham procedure in addition to standard stroke care. The study will assess the efficacy and safety of this personalized brain stimulation approach and support planning for future confirmatory trials.",[58],"Ischemic Stroke",[60,61,62,63,64],"ishchemic stroke","Lesion network mapping","Continuous theta-burst stimulation","Motor function","Neuronavigation","NOT_YET_RECRUITING","2026-08-16",{"date":68,"type":34},"2026-08-18",{"date":70,"type":22},"2026-08-26",{"date":38,"type":22},{"name":40,"class":41},{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":91,"locationsCount":42},"100642075","phase-3-a-phase-3-trial-of-lesion-network-mapping-guided-ctbs-for-motor-recovery-after-acute-ischemic-stroke-100642075","NCT07645586","A Phase 3 Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After Acute Ischemic Stroke","Lesion Network Mapping-Navigated Continuous Theta-Burst Stimulation for Motor Recovery in Acute Ischemic Stroke: A Randomized, Double-Blind, Sham-Controlled, Multicentre Phase 3 Trial: MASTRE-3","MASTRE-3",{"count":81,"type":22},584,[83],"PHASE3","This Phase 3 study will evaluate whether lesion network mapping-guided continuous theta burst stimulation (cTBS) can improve recovery after acute ischemic stroke. The treatment uses each participant's brain imaging to identify individualized stimulation targets related to stroke symptoms. Participants will receive either active cTBS or a sham procedure in addition to standard stroke care. The study will assess whether this personalized brain stimulation approach improves functional recovery and is safe for patients after ischemic stroke.",[58],[60,61,62,63,64],{"date":68,"type":34},{"date":89,"type":22},"2026-10-01",{"date":38,"type":22},{"name":40,"class":41},{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":17,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":42},"100641069","high-density-flexible-ecog-for-epilepsy-surgery---a-single-arm-ect-100641069","NCT07656857","High-density Flexible μECoG for Epilepsy Surgery - A Single-Arm ECT","Precision Resection of the Epileptogenic Zone Using Intraoperative Submillimeter Micro-Electrocorticography (Epi-PRECISE): A Single-Arm Trial With an External Historical Control Cohort","Epi-PRECISE","Inclusion Criteria:\n\n1. Age 3 to 60 years.\n2. Diagnosis of drug-resistant epilepsy, defined as persistent seizures despite treatment with two or more appropriately selected, adequately dosed and adequately tried antiseizure medications.\n3. Diagnosis of focal epilepsy after standard presurgical evaluation and considered suitable for resective epilepsy surgery.\n4. Preoperative cognitive or developmental status sufficient to participate in study assessments, as judged by the investigator and assessed using age-appropriate validated instruments. For participants aged 3 to 6 years, developmental status must be within the normal range according to the Griffiths Mental Development Scales. For participants aged 6 to 16 years, cognitive function must be within the normal range according to the Wechsler Intelligence Scale for Children. For participants older than 16 years, a Mini-Mental State Examination score of 24 or higher will be required.\n5. Written informed consent provided by the participant or, when applicable, by a legal guardian.\n\nExclusion Criteria:\n\n1. Suspected mesial temporal lobe epilepsy after multidisciplinary presurgical evaluation.\n2. History of any previous neurosurgical craniotomy before epilepsy surgery.\n3. Severe psychiatric, cognitive, or psychological disorder that prevents participation in the study or completion of follow-up.\n4. Contraindication to surgery.","3 Years","60 Years",{"count":103,"type":22},85,[25],"What's the clinical value of high-density flexible microelectrocorticography (μECoG) for guiding the resection of epileptogenic zone (EZ) in epilepsy surgery?",[107,108],"Focal Epilepsy","Intraoperative Monitoring",[110,111],"Epilepsy surgery","microelectrocorticography (μECoG)","2026-08-12",{"date":114,"type":34},"2026-08-13",{"date":116,"type":22},"2026-09-01",{"date":118,"type":22},"2028-12-31",{"name":40,"class":41},{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":42},"100651410","transcutaneous-auricular-vagus-nerve-stimulation-for-recovery-of-consciousness-after-surgery-for-spontaneous-intracerebral-hemorrhage-100651410","NCT07761507","Transcutaneous Auricular Vagus Nerve Stimulation for Recovery of Consciousness After Surgery for Spontaneous Intracerebral Hemorrhage","Efficacy and Mechanisms of Transcutaneous Auricular Vagus Nerve Stimulation for Promoting Recovery of Consciousness After Surgery for Spontaneous Intracerebral Hemorrhage: A Multicenter, Prospective, Double-Blind, Randomized, Sham-Controlled Trial","TAVNS-SICH","Inclusion Criteria:\n\n* Spontaneous intracerebral hemorrhage.\n* Age 18 to 75 years.\n* Surgical intervention performed within 48 hours after symptom onset.\n* Glasgow Coma Scale score of 5 to 9 on postoperative day 5 while the participant is not sedated; for intubated participants, the verbal component is scored as 1T.\n* Surgical hematoma evacuation by craniotomy, endoscopic evacuation, or minimally invasive aspiration\u002Ffragmentation.\n* Written informed consent provided by the participant's legally authorized representative.\n\nExclusion Criteria:\n\n* • Intracranial hemorrhage caused by a confirmed intracranial aneurysm, cerebral vascular malformation, intracranial tumor, arterial thrombosis, or venous thrombosis.\n\n  * Injury to critical brain structures affecting consciousness, including brainstem hemorrhage or thalamic hemorrhage greater than 20 mL.\n  * Isolated intraventricular hemorrhage.\n  * Severe cardiomyopathy, heart failure, atrial fibrillation, frequent premature beats, second-degree or higher atrioventricular block, or another severe cardiac arrhythmia.\n  * Unstable postoperative vital signs, defined as systolic blood pressure below 90 mm Hg or heart rate below 50 beats per minute.\n  * New cerebral infarction or recurrent intracranial hemorrhage between surgery and randomization.\n  * Acute myocardial ischemia or myocardial infarction between surgery and randomization.\n  * Previous vagus nerve electrical stimulation, previous cervical vagotomy, concurrent use of another stimulation device, or presence of an implanted electronic medical device, including a muscle stimulator, cardiac pacemaker, hearing aid, or any other implanted electronic device.\n  * Skin breakdown, infection, erythema, or another condition at the electrode-placement site that makes taVNS unsuitable.\n  * Pregnant, peripartum, or postpartum women.\n  * Current participation in another clinical trial.","75 Years",{"count":130,"type":22},160,[25],"Disorders of consciousness are common after surgery for severe spontaneous intracerebral hemorrhage and are associated with high mortality, disability, and long-term dependence. Transcutaneous auricular vagus nerve stimulation (taVNS) is a noninvasive neuromodulation technique that may enhance arousal-network activity, modulate secondary brain injury, and promote recovery of consciousness.\n\nThis multicenter, prospective, double-blind, randomized, sham-controlled trial will enroll 160 adults aged 18 to 75 years who underwent hematoma evacuation within 48 hours after spontaneous intracerebral hemorrhage and have a Glasgow Coma Scale score of 5 to 9 on postoperative day 5 while not sedated. Participants will be assigned 1:1 to active taVNS or sham stimulation for 8 hours once daily for 6 weeks. The primary outcome is the proportion of participants who remain in a disorder of consciousness (unresponsive wakefulness syndrome\u002Fvegetative state or minimally conscious state) at postoperative day 90, determined using the Coma Recovery Scale-Revised by blinded assessors.\n\nNested mechanistic substudies will investigate how taVNS may affect recovery through multimodal assessment of structural and functional brain networks, cerebral perfusion, electrophysiology, autonomic function, and circulating or cerebrospinal-fluid biomarkers. Depending on clinical stability, site capability, sample availability, and additional consent, assessments may include computed tomography, computed tomography angiography and perfusion, structural and functional magnetic resonance imaging, diffusion imaging, arterial spin labeling, electroencephalography, blood samples, and cerebrospinal fluid obtained during clinically indicated procedures.",[134,135],"Disorders of Consciousness","Spontaneous Intracerebral Hemorrhage",[137,138,139,140,141],"Spontaneous intracerebral hemorrhage","Postoperative disorder of consciousness","Transcutaneous auricular vagus nerve stimulation","Recovery of consciousness","Coma Recovery Scale-Revised","2026-08-11",{"date":112,"type":34},{"date":145,"type":22},"2026-08",{"date":147,"type":22},"2027-12",{"name":40,"class":41},{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":42},"100651578","evaluating-antiplatelet-and-physical-therapy-for-slowing-progression-in-mild-moyamoya-disease-100651578","NCT07762547","Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.","Study on the Effects of Pharmacological and Physical Therapy in Delaying the Progression of Moyamoya Disease (Moyamoya Syndrome) : Randomized Controlled Study","MOUNT-EASE","History of any form of intracranial hemorrhage, including subarachnoid hemorrhage, intracerebral hemorrhage, intraventricular hemorrhage, etc.; history of symptomatic ischemic stroke; frequent transient ischemic attacks (TIAs) before enrollment, defined as ≥3 episodes within 7 days; or history of epileptic seizures.\n\nConcomitant cerebrovascular diseases that may significantly affect perioperative risk or outcome assessment, such as intracranial aneurysms requiring concomitant treatment, cerebral arteriovenous malformations, arteriovenous fistulas, or other relevant cerebrovascular lesions.\n\nHistory of severe traumatic brain injury, brain tumor, encephalitis, meningitis, or other inflammatory diseases of the central nervous system; other major intracranial diseases; any prior invasive intracranial treatment; or history of cranial radiotherapy.\n\nPlanned cerebral revascularization surgery within 3 months. Severe cardiac dysfunction (left ventricular ejection fraction \\\u003C50% or New York Heart Association \\[NYHA\\] class III-IV), hepatic dysfunction (alanine aminotransferase \\[ALT\\] or aspartate aminotransferase \\[AST\\] \\>2 times the upper limit of normal), or renal dysfunction (serum creatinine \\>1.5 times the upper limit of normal); major systemic diseases such as unstable angina, acute coronary syndrome, asthma, or chronic obstructive pulmonary disease (COPD); severe noncardiovascular comorbidities with an expected survival of \\\u003C1 year; or any other serious comorbidity considered by the investigator to significantly increase study-related risk.\n\nContraindications to aspirin, including:\n\n1. Known allergy to aspirin;\n2. Severe renal dysfunction (serum creatinine \\>1.5 times the upper limit of normal) or severe hepatic dysfunction (ALT or AST \\>2 times the upper limit of normal);\n3. Severe heart failure (NYHA class III-IV);\n4. Coagulation disorders or a history of systemic bleeding;\n5. History of thrombocytopenia or neutropenia;\n6. History of drug-induced hematologic disorders or hepatic injury;\n7. White blood cell count \\\u003C2×10⁹\u002FL or platelet count \\\u003C100×10⁹\u002FL;\n8. History of gastrointestinal bleeding within 3 months before enrollment, or a documented history of gastric ulcer or gastritis;\n9. Any other contraindication to aspirin.\n\nContraindications to remote ischemic conditioning (RIC), including:\n\n1. Peripheral vascular disease of the upper or lower extremities, particularly significant stenosis or occlusion of the brachial, ulnar, or radial arteries, or any condition considered by the investigator to make upper-arm cuff inflation for RIC unsuitable;\n2. Conditions that may affect the safety of upper-limb RIC, including but not limited to severe skin or soft-tissue infection or injury, marked lymphedema, arteriovenous fistula or dialysis fistula, recent deep venous thrombosis, or inability to tolerate upper-arm cuff inflation as judged by the investigator, such as severe pain or recurrent subcutaneous bleeding;\n3. Known allergy to the RIC device or any of its component materials. Requirement for aspirin and\u002For other antiplatelet therapy because of diseases other than moyamoya disease, such as systemic, circulatory, or hematologic disorders; or continuous use of other antiplatelet agents for ≥5 days before enrollment, with the last dose administered within 10 days before enrollment.\n\nRequirement for anticoagulant therapy, including conditions such as atrial fibrillation, prosthetic heart valves, known or suspected endocarditis, venous thrombosis, or other diseases requiring anticoagulation; or use of heparin or oral anticoagulants within 10 days before enrollment.\n\nPregnancy, suspected pregnancy (defined as a positive pregnancy test in a woman of childbearing potential who has not used effective contraception), or breastfeeding.\n\nConditions that may interfere with completion of key follow-up assessments, such as severe cognitive impairment or psychiatric disorders resulting in inability to cooperate with study evaluations, or a clear expectation that follow-up cannot be completed.\n\nCurrent participation in another interventional clinical trial that, in the investigator's judgment, may interfere with assessment of the study outcomes","70 Years",{"count":159,"type":22},724,[25],"Moyamoya disease (MMD) is a chronic occlusive cerebrovascular disease characterized by progressive stenosis or occlusion at the terminal portion of the internal carotid artery, with formation of an abnormal vascular network at the base of the brain. Moyamoya syndrome (MMS) has the same cerebrovascular imaging and clinical manifestations as moyamoya disease, but it is accompanied by other systemic comorbidities. Moyamoya disease and moyamoya syndrome are collectively referred to as moyamoya-like cerebrovascular disease. They are highly prevalent in East Asia, and China has a large patient population. In 2018, the incidence was 1.6 per 100,000 person-years, and the disease is a major cause of stroke in children, adolescents, and young adults \\[1\\]. This group of diseases often causes severe complications such as stroke and cognitive impairment, leading to poor prognosis and reduced ability to live independently \\[2\\]. Among patients who do not receive effective treatment, the risk of severe neurological deficit or death is as high as 75%, and approximately 60% of patients with moyamoya disease develop cognitive impairment \\[3\\]. Therefore, moyamoya disease (moyamoya syndrome) is a major health problem that seriously affects the health of the Chinese population.\n\nAt present, several urgent problems remain in the clinical diagnosis and treatment of moyamoya disease (moyamoya syndrome). First, the epidemiological characteristics and disease susceptibility of this condition in the Chinese population are not yet fully clear. Second, reliable clinical assessment tools and standardized risk prediction models for moyamoya disease are lacking, and there is still no clear basis for identifying which patients need timely intervention. Third, a systematic precision treatment pathway for moyamoya disease has not yet been established, and high-quality evidence is still lacking regarding the role of pharmacological and physical therapy in delaying disease progression. Therefore, systematic research to clarify the efficacy of different treatment approaches in moyamoya disease is of great significance for promoting the establishment of an integrated diagnostic and therapeutic system for this disease.\n\n\\[Add a paragraph introducing ischemic conditioning and its role in stroke and MMD.\\] Systematic treatment is an important means to improve the prognosis of moyamoya disease. Current major treatment options include revascularization surgery and pharmacological therapy. Previous studies have shown that revascularization surgery can improve cerebral blood flow and reduce the risk of stroke; however, for asymptomatic or early-stage patients, surgery is not the only option \\[4\\]. In terms of pharmacological therapy, nonsurgical treatments such as antiplatelet therapy and intensive lipid-lowering therapy may delay disease progression, but high-quality clinical evidence remains lacking. In addition, emerging physical therapies such as ischemic conditioning have been shown to improve the tolerance of brain tissue to ischemia and have demonstrated potential therapeutic value in patients with stroke \\[5\\]. However, the safety and efficacy of these treatment approaches in patients with moyamoya disease require further study and validation.\n\nTherefore, this study proposes to conduct a multicenter, prospective randomized controlled clinical trial to systematically evaluate the efficacy and safety of aspirin therapy and ischemic conditioning therapy in delaying the progression of moyamoya disease, and to provide evidence-based support for nonsurgical treatment strategies for patients with moyamoya disease.\n\n\\[The following content was moved from the study rationale section and should be integrated with the research background.\\] Even when patients with moyamoya disease (moyamoya syndrome) have not yet developed definite symptoms of cerebral infarction, their cerebral hemodynamics may already be in a compensated or critical state. They are often prone to nonspecific symptoms such as headache and dizziness, subjective cognitive decline, and TIA attacks, and they have a potential risk of progression to symptomatic stroke. Microembolus formation and vascular endothelial dysfunction may further reduce flow reserve and aggravate hypoperfusion, thereby leading to adverse events. For such mildly affected patients, early intervention has important clinical value for delaying disease progression and preventing cerebrovascular events.\n\nAspirin irreversibly inhibits cyclooxygenase-1 and blocks thromboxane A2 production, thereby inhibiting platelet aggregation. In the pathological process of moyamoya disease (moyamoya syndrome), microcirculatory changes and vascular intimal injury may activate platelets and promote microthrombus formation, which may aggravate ischemia-induced stroke. Therefore, aspirin may reduce the risk of ischemic events by inhibiting platelet aggregation. Ischemic conditioning is a noninvasive physical therapy that activates systemic endogenous protect",[163,164,165,166],"Moyamoya Disease","Moyamoya Syndrome","Aspirin","Remote Ischemic Conditioning","2026-08-09",{"date":114,"type":34},{"date":170,"type":22},"2026-07-15",{"date":172,"type":22},"2030-02-28",{"name":40,"class":41},{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":17,"minAge":181,"maxAge":128,"enrollmentInfo":182,"targetDuration":4,"studyType":23,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":4},"100651168","multisensory-40-hz-stimulation-for-alzheimers-disease-100651168","NCT07758751","Multisensory 40-Hz Stimulation for Alzheimer's Disease","A Randomized, Sham-Controlled Study of the Safety and Efficacy of Multisensory 40-Hz Stimulation in Patients With Alzheimer's Disease","Inclusion Criteria:\n\n1. Provision of written informed consent by the participant or the participant's legally authorized representative.\n2. Age 45 to 75 years, inclusive.\n3. Completion of at least primary school education.\n4. Diagnosis within the Alzheimer's disease spectrum according to the National 5.Institute on Aging and Alzheimer's Association criteria.\n\nMild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia, defined by a Montreal Cognitive Assessment score of ≤24 for participants with middle school education or above, or ≤23 for participants with primary school education, and a Clinical Dementia Rating global score of 0.5 or 1.\n\n6.Evidence of Alzheimer's disease pathology based on a positive positron emission tomography, cerebrospinal fluid, or blood biomarker result.\n\n7.Alzheimer's disease-related medications are expected to remain stable during the study period.\n\nExclusion Criteria:\n\n1. Current or previous history of a neurological disorder other than Alzheimer's disease that may affect cognition or study assessments, including epilepsy, stroke, multiple sclerosis, poorly controlled migraine, intracranial injury, previous neurosurgery, or head trauma with residual neurological impairment.\n2. Contraindication to magnetic resonance imaging, electroencephalography, auditory stimulation, visual stimulation, or noninvasive brain stimulation.\n3. Current major depressive disorder or another psychiatric disorder that, in the investigator's judgment, may interfere with study participation or outcome assessment.\n4. Clinically significant structural abnormalities on brain magnetic resonance imaging, including hydrocephalus, stroke, or another structural lesion that may confound study results.\n5. Severe cardiovascular or pulmonary disease.\n6. Cognitive impairment primarily attributable to another disorder, including frontotemporal dementia, dementia with Lewy bodies, Parkinson's disease dementia, or vascular dementia.\n7. Clinically significant suicide risk or a suicide attempt within the previous 12 months.\n8. Behavioral disturbance, including severe aggression, agitation, or impulsivity, that may interfere with adherence to study procedures.\n9. Current or planned treatment with an anti-amyloid monoclonal antibody during the study period.\n10. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.","45 Years",{"count":53,"type":22},[25],"This study aims to evaluate the safety and preliminary efficacy of combined auditory and visual 40-Hz stimulation in participants with biomarker-confirmed Alzheimer's disease spectrum disorders. A total of 60 participants with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia will be randomly assigned in a 1:1 ratio to receive either active multisensory 40-Hz stimulation or sham stimulation. The intervention will be administered for 60 minutes once daily for 4 consecutive weeks. Clinical assessments, electroencephalography, multimodal magnetic resonance imaging, and blood biomarkers will be evaluated before and after the intervention. Additional clinical, electroencephalographic, and blood biomarker assessments will be performed at 3 and 6 months after the intervention.",[186],"Alzheimer Disease",[188,189,190,191,192],"Alzheimer's disease","Mild cognitive impairment","Gamma entrainment","40-Hz stimulation","Multisensory stimulation","2026-08-06",{"date":142,"type":34},{"date":196,"type":22},"2026-09",{"date":198,"type":22},"2027-10-30",{"name":40,"class":41},{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":23,"phases":210,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":4},"100650727","phase-1-efficacy-and-safety-of-pregabalin-combined-with-educational-and-behavioral-intervention-for-bladder-pain-syndromeinterstitial-cystitis-100650727","NCT07752134","Efficacy and Safety of Pregabalin Combined With Educational and Behavioral Intervention for Bladder Pain Syndrome\u002FInterstitial Cystitis","A Multicenter Randomized Controlled Trial Assessing the Efficacy and Safety of Pregabalin Combined With Educational and Behavioral Intervention Program for Bladder Pain Syndrome\u002FInterstitial Cystitis","PEBI-ICBPS","Inclusion Criteria:- Adults aged 18 years and older\n\n* Clinically diagnosed with bladder pain syndrome\u002Finterstitial cystitis (IC\u002FBPS) in accordance with diagnostic criteria released by AUA and ESSIC, with confounding disorders excluded through clinical workup\n* Persistent urinary symptoms across most days in the latest 3 months prior to enrollment\n* Participants report bladder pain\u002Fdiscomfort and urinary urgency\u002Ffrequency scores ≥ 3 on the 0-10 Likert scale over the past 4 weeks\n\nExclusion Criteria:- Symptomatic urethral stricture\n\n* Active neurological diseases that impair bladder or intestinal function\n* Active autoimmune disorders or infectious diseases\n* History of cystitis secondary to tuberculosis, pelvic radiotherapy or pelvic chemotherapy\n* Previous history of non-cutaneous malignant tumors\n* Confirmed severe psychiatric disorders at present, including major depressive disorder, bipolar disorder, schizophrenia and other serious mental illnesses\n* Severe systemic diseases featuring obvious dysfunction of the heart, lung, liver or kidney\n* Confirmed hypersensitivity to pregabalin\n* Concomitant use of additional antibiotics or nonsteroidal anti-inflammatory drugs (NSAIDs)\n* Pregnancy status\n* Lactation period",{"count":209,"type":22},200,[211],"PHASE1","Bladder pain syndrome\u002Finterstitial cystitis (IC\u002FBPS) brings long-term pelvic pain, frequent urination and poor sleep quality, which severely lowers patients' daily life quality. Educational and behavioral management program (EBMP) is a mainstream non-drug treatment for IC\u002FBPS, yet a considerable proportion of patients fail to achieve satisfying symptom relief via EBMP alone. This multicenter randomized controlled trial aims to compare the efficacy and safety of pregabalin combined with EBMP versus EBMP monotherapy in adult IC\u002FBPS patients.\n\nA total of 140 eligible adult participants fulfilling AUA and ESSIC diagnostic criteria for IC\u002FBPS will be randomized at a 1:1 ratio into two groups. The control group receives standalone EBMP intervention, while the intervention group obtains EBMP plus pregabalin with flexible dosage titration. Pregabalin starts at 150 mg per day, and doses can be gradually adjusted up to a maximum daily limit of 600 mg according to patients' tolerance and symptom improvement during the 12-week intervention period.\n\nAll enrolled participants will complete standardized symptom questionnaires, pain scoring and voiding diary assessments at predefined follow-up time points. The primary outcome is treatment response measured by Global Response Assessment (GRA) after 12 weeks of intervention. Secondary evaluations cover VAS pain scores, PUF, ICSI, ICPI scales, bladder functional parameters, quality of life, sleep status and depressive symptoms. Researchers will track all adverse events throughout follow-up to judge the safety of combined treatment. Findings from this trial can offer optimized treatment options for adults diagnosed with IC\u002FBPS.",[214,215,216,217],"Bladder Pain Syndrome","Pregabalin","Educational Behavioral Intervention","Urinary Urgency",{"date":219,"type":34},"2026-08-07",{"date":221,"type":22},"2026-12-31",{"date":223,"type":22},"2027-12-31",{"name":40,"class":41},{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":233,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":249,"locationsCount":42},"100561939","early-phase-1-a-study-of-the-safety-and-tolerability-of-ga-in-the-treatment-of-patients-with-refractory-neuropathic-pain-100561939","NCT06596681","A Study of the Safety and Tolerability of GA in the Treatment of Patients With Refractory Neuropathic Pain","Inclusion Criteria:\n\n1. Patients with a definitive diagnosis of neuropathic pain, including but not limited to painful diabetic peripheral neuropathy, trigeminal neuralgia, and post-stroke pain, aged 18-65 years old (regardless of gender), with:\n\n   1. Regularised treatment with conventional medical therapy (including, but not limited to, medication, physiotherapy, cognitive therapy, nerve blocks and other non-invasive or minimally invasive treatments) for at least 3 months with no symptomatic relief or emergence of tolerance, as assessed by the investigator\n   2. Pharmacological treatment means a full course of treatment with at least two first-line medications, as assessed by the investigator\n2. Mean visual analogue scale (VAS) value ≥4 cm and\u002For mean numerical rating scale (NRS) value ≥4 points within one week of baseline at enrolment\n3. Subjects who have had a stable analgesic regimen for at least 30 days prior to the intensity of pain described in Inclusion Criterion 2 and agree not to arbitrarily change the type and dose of medication that they are currently taking until the end of the period of assessment of the effectiveness of this trial, as assessed by the investigator\n4. Subjects volunteered to participate in the trial and gave fully informed consent to sign an informed consent form\n5. Have stable neurological status as assessed by the researcher through motor, sensory and reflex functions\n6. Subjects are considered reliable and able to comply with the trial protocol (e.g., able to understand and complete relevant scales), visit protocols, and medication administration, according to the investigator's judgement\n7. Subjects of childbearing potential agree to sign an informed consent form and have no plans to have children during the study period and voluntarily use effective contraception (oral contraceptives are prohibited) and do not plan to donate sperm or eggs\n\nExclusion Criteria:\n\n* 1.In patients with painful diabetic peripheral neuropathy, amputation due to diabetes mellitus or large (≥3cm) and\u002For gangrenous ulcers on the lower limbs 2.Currently diagnosed with progressive neurological disorders such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, tumours of the brain or spinal cord, and neurodegenerative disorders, as determined by the investigators 3.Have a chronic systemic disease that, as assessed by the investigator, may affect the subject's participation in the study, including but not limited to:\n\n  1. suffering from severe cardiopulmonary disease such as unstable angina, myocardial infarction, severe arrhythmia, recurrent asthma attacks, etc;\n  2. Malignant tumours of the central nervous system or other systems. 4.Current status such as coagulation disorders, bleeding tendencies, platelet dysfunction, severely reduced function due to underlying cardiac\u002Fpulmonary disease, progressive peripheral vascular disease, or poorly controlled diabetes mellitus, and subjects who may be suffering from a relevant disease state that affects surgery as assessed by the investigator 5.Currently on anticoagulants and unable to stop them 6.Localised infection or active systemic infection at the anticipated surgical access site 7.History of previous intracranial surgical treatment (except for minimally invasive paracentesis for diagnostic tests, etc.) 8.Patients with severe psychiatric symptoms (e.g., major depression, schizophrenia, etc.) or significant suicidal tendencies or assessed by the investigator to be unable to complete the clinical trial 9. Pre-existing or concomitant severe hepatic dysfunction, renal dysfunction, cardiac dysfunction (in which severe hepatic dysfunction is defined as ALT ≥ 2.0 times the upper limit of normal or AST ≥ 2.0 times the upper limit of normal; severe renal dysfunction refers to a CRE ≥ 1.5 times the upper limit of normal or an eGFR \\\u003C 40mL\u002Fmin\u002F1.73m2; and severe cardiac dysfunction refers to an NYHA score of grade 3-4) ，delirium, hypotension, epilepsy, glaucoma, myelosuppression or leukopenia, severe central nervous system depression, or coma from any cause 10. Subjects with abnormal laboratory test values:\n\n  \u003C!-- -->\n\n  1. white blood cell count \\\u003C3.5 x 109\u002FL and neutrophil count \\\u003C1.0 x 109\u002FL\n  2. Platelet (PLT) \\\u003C75 x 109\u002FL\n  3. Coagulation: prothrombin time and activated partial thromboplastin time \\>1.5 x ULN\n  4. Blood adeno-associated virus (AAV) antibody titre \\>1:1000 11.Patients taking drugs that cause granulocyte deficiency or have myelosuppressive effects 12.Patients with granulocyte deficiency or severe granulocytopenia due to prior clozapine use 13.Patients with contraindications and\u002For allergies to medications during the trial (e.g. clozapine or other components of clozapine, contrast agents, etc.) 14.Have gastrointestinal diseases (Crohn's disease, acute or chronic pancreatitis, paralytic intestinal obstruction, etc.) or major gastrointestinal surgeries that affect the absorption, metabolism and excretion of drugs, etc.\n\n     15.Subjects had received any gene or cellular therapy 16. Known history of alcohol, drug abuse 17.Patients participating in other clinical trials or applying other investigational biologics, drugs or devices within six months prior to screening 18.Contraindications to MRI and functional MRI (e.g. claustrophobia, metallic foreign bodies in the body) 19.Clozapine-related serious adverse reactions are considered a screening failure if they occur during the screening period, at the judgement of the investigator",{"count":232,"type":22},6,[234],"EARLY_PHASE1","Previous studies have shown that the anterior cingulate cortex is involved in the regulation of pain and its associated negative emotions, that pyramidal neurons are highly excitable in chronic neuropathic pain conditions, and that silencing of pyramidal neurons can eliminate pain. The aim of this study was to evaluate the safety, tolerability, and efficacy of intracranial injection of GA (containing the hM4Di gene) in the anterior cingulate cortex in combination with oral clozapine for the treatment of refractory neuropathic pain.",[237],"Pain, Intractable",[239,240,241,242],"Refractory neuropathic pain","GA","clozapine","safety","2026-07-30",{"date":245,"type":34},"2026-07-31",{"date":247,"type":34},"2024-09-11",{"date":221,"type":22},{"name":40,"class":41},{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":267,"leadSponsor":269,"locationsCount":42},"100649541","venlafaxine-for-non-specific-low-back-pain-100649541","NCT07737158","Venlafaxine for Non-specific Low Back Pain","Efficacy and Safety of Venlafaxine in the Treatment of Non-specific Low Back Pain","Inclusion Criteria:\n\n* Adults aged 18 to 75 years.\n* Diagnosis of chronic nonspecific low back pain, defined as pain located below the costal margin and above the inferior gluteal folds, lasting for more than 3 months, without a specific pathological cause.\n* Moderate to severe pain, defined as a Numerical Rating Scale score of 3 or higher.\n* Able to understand the study procedures and sign written informed consent.\n\nExclusion Criteria:\n\n* Low back pain caused by a known specific pathological condition, including but not limited to fracture, malignancy, infection, inflammatory disease, or other identifiable structural or systemic causes.\n* Major comorbidities that may interfere with study outcomes or represent contraindications to the study medication.\n* Current or previous diagnosis of depression, regardless of whether treatment was received.\n* Current or previous use of antidepressant medication.\n* Current use of opioid analgesics.\n* Pregnancy, breastfeeding, or planned pregnancy during the study period.\n* Known allergy, hypersensitivity, or contraindication to toludesvenlafaxine.\n* History of psychosis or other major psychiatric disorders.\n* Any condition that, in the investigator's judgment, makes the participant unsuitable for the study.",{"count":258,"type":22},228,[25],"Chronic non-specific low back pain is the leading cause of productivity loss and disability worldwide, constituting a major public health challenge. This study aims to systematically evaluate and compare the role of the antidepressant drug Venlafaxine in chronic non-specific low back pain, which is of critical importance for optimising clinical practice and developing precise, individualised treatment regimens.",[262,263],"Non-specific Low Back Pain","Pain Management","2026-07-27",{"date":243,"type":34},{"date":116,"type":22},{"date":268,"type":22},"2028-12-30",{"name":40,"class":41},{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":128,"enrollmentInfo":276,"targetDuration":4,"studyType":23,"phases":278,"briefSummary":279,"conditions":280,"keywords":281,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":286,"leadSponsor":288,"locationsCount":42},"100647486","toludesvenlafaxine-for-non-specific-low-back-pain-100647486","NCT07709416","Toludesvenlafaxine for Non-specific Low Back Pain","Efficacy and Safety of Toludesvenlafaxine in the Treatment of Non-specific Low Back Pain",{"count":277,"type":22},132,[25],"Chronic non-specific low back pain is the leading cause of productivity loss and disability worldwide, constituting a major public health challenge. This study aims to systematically evaluate and compare the role of the antidepressant drug toludesvenlafaxine in chronic non-specific low back pain, which is of critical importance for optimising clinical practice and developing precise, individualised treatment regimens.",[262],[282,262],"Toludesvenlafaxine","2026-07-24",{"date":264,"type":34},{"date":170,"type":34},{"date":287,"type":22},"2028-12-01",{"name":40,"class":41},{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":299,"phases":4,"briefSummary":300,"conditions":301,"keywords":304,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":42},"100595110","changes-in-rimazolen-dosage-in-patients-with-insomnia-under-intravenous-anesthesia-100595110","NCT07028190","Changes in Rimazolen Dosage in Patients With Insomnia Under Intravenous Anesthesia","Changes in Rimazolen Dosage in Patients With Insomnia Under Intravenous Anesthesia: a Prospective Cohort Study","Inclusion Criteria:\n\n* Patients with insomnia:\n\n  1. Age of 18 - 64 years;\n  2. American Society of Anesthesiologists (ASA) physical status of I - II;\n  3. Body mass index (BMI) of 15 - 30;\n  4. Patients undergoing elective thoracoscopy, laparoscopy, hysteroscopy, open abdominal surgery, open thoracic surgery, open spinal surgery, craniotomy surgery, and digestive endoscopy under general anesthesia;\n  5. Positive screening results according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for insomnia disorder;\n  6. 8-item Sleep Condition Indicator (SCI; score 0-4; range 0-32, higher score means better sleep) scored 16 or less.\n* Patients with normal sleep:\n\n  1. Age of 18 - 64 years;\n  2. ASA physical status of I - II;\n  3. BMI of 15 - 30;\n  4. Patients undergoing elective thoracoscopy, laparoscopy, hysteroscopy, open abdominal surgery, open thoracic surgery, open spinal surgery, craniotomy surgery, and digestive endoscopy under general anesthesia;\n  5. No history or evidence of insomnia.\n\nExclusion Criteria:\n\n1. Associated with any neurological disease;\n2. Daily alcohol consumption;\n3. Any contraindication to intravenous anesthetic drug, such as hypotension or shock;\n4. History of allergy to any drug used in the study;\n5. Pregnancy or breastfeeding;\n6. Patients with sleep apnea syndrome;\n7. acute upper respiratory infection;\n8. Patients with psychological diseases who report suicidal thoughts;\n9. Patients who need to work or take care of children\u002Felderly people frequently at night.","64 Years",{"count":298,"type":22},840,"OBSERVATIONAL","To compare the dosage requirement of rimazolen under intravenous anesthesia between patients with insomnia and those with normal sleep pattern.",[302,303],"Insomnia","Digestive Endoscopy",[302,305,306],"Digestive endoscopy","Rimazolen","2026-07-21",{"date":309,"type":34},"2026-07-22",{"date":311,"type":34},"2025-06-12",{"date":313,"type":22},"2027-03-31",{"name":40,"class":41},{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":296,"enrollmentInfo":321,"targetDuration":4,"studyType":299,"phases":4,"briefSummary":322,"conditions":323,"keywords":324,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":326,"startDateStruct":327,"completionDateStruct":328,"leadSponsor":329,"locationsCount":42},"100595109","changes-in-etomidate-dosage-in-patients-with-insomnia-undergoing-intravenous-anesthesia-100595109","NCT07028177","Changes in Etomidate Dosage in Patients With Insomnia Undergoing Intravenous Anesthesia","Changes in Etomidate Dosage in Patients With Insomnia Undergoing Intravenous Anesthesia: a Prospective Cohort Study",{"count":298,"type":22},"To compare the dosage requirement of etomidate under intravenous anesthesia between patients with insomnia and those with normal sleep pattern.",[302,303],[302,305,325],"Etomidate",{"date":309,"type":34},{"date":311,"type":34},{"date":313,"type":22},{"name":40,"class":41},{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":296,"enrollmentInfo":337,"targetDuration":4,"studyType":299,"phases":4,"briefSummary":338,"conditions":339,"keywords":340,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":343,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":347,"locationsCount":42},"100585026","changes-in-ciprofol-dosage-in-patients-with-insomnia-undergoing-intravenous-anesthesia-100585026","NCT06897007","Changes in Ciprofol Dosage in Patients With Insomnia Undergoing Intravenous Anesthesia","Changes in Ciprofol Dosage in Patients With Insomnia Undergoing Intravenous Anesthesia: a Prospective Cohort Study","Inclusion Criteria:\n\n* Patients with insomnia:\n\n  1. Age of 18 - 64 years;\n  2. ASA physical status of I - II;\n  3. BMI of 15 - 30;\n  4. Patients undergoing elective thoracoscopy, laparoscopy, hysteroscopy, open abdominal surgery, open thoracic surgery, open spinal surgery, craniotomy surgery, and digestive endoscopy under general anesthesia;\n  5. Positive screening results according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for insomnia disorder;\n  6. 8-item Sleep Condition Indicator (SCI; score 0-4; range 0-32, higher score means better sleep) scored 16 or less.\n* Patients with normal sleep:\n\n  1. Age of 18 - 64 years;\n  2. ASA physical status of I - II;\n  3. BMI of 15 - 30;\n  4. Patients undergoing elective thoracoscopy, laparoscopy, hysteroscopy, open abdominal surgery, open thoracic surgery, open spinal surgery, craniotomy surgery, and digestive endoscopy under general anesthesia;\n  5. No history or evidence of insomnia.\n\nExclusion Criteria:\n\n1. Associated with any neurological disease;\n2. Daily alcohol consumption;\n3. Any contraindication to intravenous anesthetic drug, such as hypotension or shock;\n4. History of allergy to any drug used in the study;\n5. Pregnancy or breastfeeding;\n6. Patients with sleep apnea syndrome;\n7. acute upper respiratory infection;\n8. Patients with psychological diseases who report suicidal thoughts;\n9. Patients who need to work or take care of children\u002Felderly people frequently at night.",{"count":298,"type":22},"To compare the dosage requirement of ciprofol under intravenous anesthesia between patients with insomnia and those with normal sleep pattern.",[302,303],[302,305,341,342],"Ciprofol","chronic pain",{"date":309,"type":34},{"date":345,"type":34},"2025-03-24",{"date":313,"type":22},{"name":40,"class":41},{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":23,"phases":356,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":374},"100647902","phase-2-platform-research-for-innovative-medicines-in-nf2-swn-prime-nf2-100647902","NCT07713745","Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)","PRIME-NF2","Eligibility Specific For MASTER STUDY\n\nInclusion Criteria:\n\nSubjects must satisfy all of the following criteria to be enrolled into the main study natural history observation cohort:\n\n(1) Must meet the 2022 International Consensus Criteria for NF2-SWN, defined by having at least one of the following:\n\n1. Bilateral vestibular schwannomas (VS)\n2. An identical NF2 pathogenic variant in at least 2 anatomically distinct NF2-related tumors (schwannoma, meningioma, and\u002For ependymoma). (Note: if the variant allele fraction (VAF) in unaffected tissues such as blood is clearly \\\u003C50%, the diagnosis is mosaic NF2-related schwannomatosis)\n3. Either 2 major or 1 major and 2 minor criteria as described in the following:\n\nMajor criteria:\n\n* Unilateral VS\n* First-degree relative other than sibling with NF2-related schwannomatosis\n* 2 or more meningiomas (Note: single meningioma qualifies as minor criteria).\n* NF2 pathogenic variant in an unaffected tissue such as blood (Note: if the VAF is clearly \\\u003C50%, the diagnosis is mosaic NF2-related schwannomatosis)\n\nMinor criteria:\n\nCan count \\>1 of a type (eg, 2 distinct schwannomas would count as 2 minor criteria)\n\n* Ependymoma, meningioma (Note: multiple meningiomas qualify as a major criteria), schwannoma (Note: if the major criterion is unilateral VS, at least 1 schwannoma must be dermal in location) Can count only once (eg, bilateral cortical cataracts count as a single minor criterion)\n* Juvenile subcapsular or cortical cataract, retinal hamartoma, epiretinal membrane in a person aged \\\u003C40 years, meningioma\n\n  (2) Presence of at least one evaluable lesion: Vestibular schwannoma, meningioma, or non-vestibular schwannoma: clearly identifiable lesion on contrast-enhanced T1-weighted MRI; Ependymoma: clearly identifiable lesion on contrast-enhanced T1-weighted or T2\u002FFLAIR sequences; (3) Expected ability to complete at least 12 months of follow-up assessments; (4) Ability to understand and voluntarily sign a written informed consent form, or a legally authorized guardian signs the informed consent form together ; (5) Sub-study-specific criteria (for intervention arms only): If the subject intends to enter an interventional sub-study, in addition to meeting the above main study criteria, the subject must also satisfy the specific inclusion criteria specified in that sub-study protocol (e.g., organ function, prior treatment restrictions, washout periods, etc.), as determined by the drug characteristics.\n\nExclusion Criteria:\n\nSubjects meeting any of the following criteria will not be permitted to enter the main study:\n\n1. Coexisting other genetic syndromes that may cause multiple intracranial tumors (e.g., SMARCB1\u002FLZTR1-related schwannomatosis, Cowden syndrome);\n2. Expected survival \\\u003C12 months;\n3. Presence of severe psychiatric disorders or cognitive impairment that precludes cooperation with imaging or hearing assessments;\n4. Extreme social or geographic factors that, in the investigator's judgment, may impede follow-up for more than 12 months;\n5. Sub-study-specific exclusion criteria (for intervention arms only): If the subject intends to enter an interventional sub-study, the subject must also satisfy the specific exclusion criteria specified in that sub-study protocol (e.g., specific organ dysfunction, active infection, pregnancy, etc.).",{"count":209,"type":22},[55],"This is an adaptive platform-basket trial that aims to evaluate the safety and efficacy of multiple novel agents and combination therapies in patients with NF2-related schwannomatosis (NF2-SWN). The study employs a basket design to assess treatment responses across four tumor types commonly associated with NF2-SWN: vestibular schwannomas, non-vestibular schwannomas, meningiomas, and ependymomas.\n\nA shared natural history observational cohort, receiving routine clinical follow-up without investigational treatment, serves as a common control for all substudies. The adaptive platform enables the dynamic addition or closure of substudies based on interim analyses, thereby optimizing trial efficiency.\n\nEligible patients who meet the master protocol criteria and satisfy substudy-specific safety requirements will be assigned to receive the corresponding intervention. Currently open substudies include:\n\n* Substudy A: Selumetinib\n* Substudy B: Luvometinib plus Serplulimab",[359,360,361,362,363,364,365],"Neurofibromatosis Type 2","Vestibular Schwannoma","Non-vestibular Schwannoma","Meningioma","Ependymoma","NF2-related Schwannomatosis","NF2","2026-07-14",{"date":368,"type":34},"2026-07-20",{"date":370,"type":22},"2026-07-18",{"date":372,"type":22},"2036-12-31",{"name":40,"class":41},5,{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":17,"minAge":100,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":23,"phases":385,"briefSummary":386,"conditions":387,"keywords":388,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":394,"leadSponsor":395,"locationsCount":42},"100647361","phase-2-selumetinib-for-nf2-related-schwannomatosis-100647361","NCT07707947","Selumetinib for NF2-Related Schwannomatosis","A Single-Center, Single-Arm, Phase II Study to Explore the Efficacy and Safety of MEK1\u002F2 Inhibitor (MEKi) Selumetinib in the Treatment of Patients With NF2-Related Schwannomatosis","ASSIST","Inclusion Criteria:\n\n1. Patients must have a pathogenic variant in the NF2 gene (either in the germline or in two NF2-related tumors)OR a confirmed diagnosis of NF2 by fulfilling National Institute of Health (NIH)criteria or Manchester criteria:\n\n   The genetic test report should be issued by companies or hospitals with corresponding qualifications.\n\n   The NIH criteria includes presence of:\n   * Bilateral vestibular schwannomas, OR\n   * First-degree relative with NF2 and EITHER unilateral eighth nerve mass OR two of the following: neurofibroma, meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity.\n\n   The Manchester criteria includes presence of:\n   * Bilateral vestibular schwannomas, OR\n   * First-degree relative with NF2 and EITHER unilateral eighth nerve mass OR two of the following: neurofibroma, meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity, OR\n   * Unilateral vestibular schwannoma AND any two of: neurofibroma, meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity,OR\n   * Multiple meningiomas (two or more)AND unilateral vestibular schwannoma OR\n   * any two of: schwannoma, glioma, neurofibroma, cataract.\n2. Subjects must have ≥1 measurable target vestibular schwannoma meeting all of the following conditions:\n\n   * Measurable on MRI with a minimum diameter ≥3 mm;\n   * Evidence of radiographic progression within the past 36 months according to REiNS criteria, OR documented clinical progression attributable to the target tumor (e.g., hearing decline, cranial nerve dysfunction).\n   * Subjects whose Word Recognition Score (WRS)ranging from 50%to 88%at the side of target vestibular schwannoma.\n3. The target tumor must be considered not amenable to surgery due to:\n\n   * High surgical risk (e.g., risk of neurological deficit), OR\n   * Patient refusal of surgery after adequate medical counseling.\n4. Male or female subjects aged ≥3 years at the time of informed consent.\n5. Adequate functional status\n\n   Subjects aged ≥16 years:\n   * Karnofsky Performance Status ≥70,OR\n   * ECOG Performance Status 0-1\n\n   Subjects aged \\\u003C16 years:\n   * Lansky Performance Status ≥70\n   * Adequate organ and bone marrow function\n6. Laboratory values obtained within 28 days prior to enrollment must meet the following:\n\n   1. Hematologic function\n\n      * Hemoglobin ≥9.0 g\u002FdL\n      * Absolute neutrophil count (ANC)≥1.5 ×10⁹\u002FL\n      * Platelet count ≥100 ×10⁹\u002FL\n   2. Hepatic function\n\n      * AST and ALT ≤2.5 ×ULN (≤2.0 ×ULN for pediatric subjects)\n      * Total bilirubin ≤ 1.5 ×ULN (≤3 ×ULN in subjects with documented Gilbert's syndrome)\n   3. Renal function\n\n      * Serum creatinine ≤1.5 ×ULN, OR\n      * Creatinine clearance ≥60 mL\u002Fmin\u002F1 .73 m²(age-and BSA-adjusted)\n   4. Cardiac function\n\n      * Left ventricular ejection fraction (LVEF)≥50%by echocardiography\n      * No clinically significant uncontrolled cardiac disease\n   5. Pulmonary function • Peripheral oxygen saturation ≥92%on room air\n7. Reproductive and contraception requirements\n\n   1. Females of childbearing potential\n\n      * Negative serum or urine pregnancy test prior to enrollment\n      * Must be postmenopausal ≥12 months, surgically sterile, or using a highly effective method of contraception throughout the study and for 3 months after the last dose\n      * Acceptable methods include:\n\n        * Hormonal contraception\n        * Intrauterine device (IUD)\n        * Long-acting reversible contraception\n        * Tubal ligation\n      * Oral contraception alone must be combined with a barrier method\n   2. Males • Must be surgically sterile or agree to use barrier contraception with permicide during treatment and for 3 months after the last dose.\n8. Subjects must be able to swallow selumetinib capsules intact.\n9. Written informed consent must be obtained:\n\n   * From the subject if capable of providing consent;\n   * From a legally acceptable representative for minors or subjects lacking full decision-making capacity.\n\nExclusion Criteria:\n\n1. Concurrent involvement in study conduct:the subject is an employee of the Sponsor, Investigator, or study site who is directly involved in the planning, conduct, or management of this clinical study.\n2. Participation in another interventional clinical trial with an investigational medicinal product, or receipt of an investigational agent within 28 days (or 5 half-lives if known and longer)prior to first dose.\n3. Prior anti-cancer systemic therapies or prior radiotherapy that, in the investigator's judgment, would confound safety or efficacy assessment, unless completed ≥28 days prior to first dose (longer washout required for agents with prolonged biologic effect as specified in protocol appendix). Subjects who received prior local therapy (surgery or localized radiotherapy)are eligible if recovery is complete and target lesion remains measurable.\n4. Evidence or high suspicion of malignant peripheral nerve sheath tumor (MPNST)or other active malignancy requiring systemic therapy (past malignancy is allowed only if disease-free for ≥2 years, except for adequately treated basal cell carcinoma or in situ carcinoma).\n5. Significant cardiac disease or ECG abnormalities:\n\n   * Resting QTcF \\>470 ms (adults)\\[\\>450 ms for pediatric thresholds as specified in protocol appendix\\], or clinically significant baseline prolongation per investigator\u002Fmedical monitor.\n   * Clinically significant arrhythmia (symptomatic ventricular tachycardia, sustained ventricular tachycardia, uncontrolled atrial fibrillation). Subjects with well controlled atrial fibrillation may be considered after Medical Monitor review.\n   * Acute coronary syndrome within 6 months, unstable angina, symptomatic congestive heart failure NYHA class II-IV, or LVEF below institutional lower limit of normal (LLN)or \\\u003C50%.\n6. Uncontrolled hypertension:systolic ≥140 mmHg or diastolic ≥90 mmHg despite optimal therapy (adult criteria);for pediatric subjects use age\u002Fheight\u002Fgender percentiles per protocol appendix.\n7. Severe hepatic or renal impairment -e.g.,AST\u002FALT \\>5 ×ULN (or per protocol specified threshold for severe impairment), total bilirubin \\>3 ×ULN (unless Gilbert's syndrome).(See inclusion for minimum acceptable labs;exclude those with more severe dysfunction.)\n8. Ophthalmologic conditions:current or prior history of MEK-associated retinopathy \u002F central serous retinopathy \u002Fretinal pigment epithelial detachment \u002Fretinal vein occlusion, or any active ocular condition judged by the investigator\u002Fophthalmologist to increase the risk of serious ocular adverse events (e.g., uncontrolled glaucoma with elevated IOP and meaningful vision at risk). Subjects with stable, chronic ophthalmic findings that are not expected to worsen with MEK inhibition may be eligible after ophthalmology clearance.\n9. Known hypersensitivity to selumetinib or any excipients.\n10. Active, uncontrolled infection including:\n\n    * Positive HIV test (known HIV infection with uncontrolled disease or on unstable antiretroviral therapy that interacts with study drug)-no evidence AIDS and no contraindicating ART may be considered after Medical Monitor review.\n    * Active hepatitis B or C infection (HBsAg positive or HCV RNA positive). Subjects with resolved HBV (HBsAg negative, anti-HBc positive)may be eligible per local hepatology guidance and prophylaxis plan.\n11. Concomitant medications that:\n\n    * Are known to prolong QT interval and cannot be safely discontinued;OR\n    * Are strong CYP3A4 or CYP2C19 inducers\u002Finhibitors that cannot be stopped and would significantly alter selumetinib exposure (refer to protocol drug-interaction appendix for permitted\u002Fforbidden lists).\n12. Gastrointestinal conditions that preclude reliable oral absorption (e.g., severe malabsorption, short bowel syndrome, recent (within 6 months)major intestinal resection)or inability to swallow intact capsules.\n13. Conditions requiring urgent neurosurgical intervention (e.g., symptomatic hydrocephalus requiring immediate shunting, life-threatening brainstem compression)-subjects requiring emergent neurosurgery are not eligible until stabilized and reevaluated.\n14. Prior organ transplantation (allogeneic)or ongoing immunosuppression that would confound safety assessment.\n15. Concomitant vitamin E†or other agents judged to have potential interaction with the study drug if they cannot be discontinued per protocol (e.g., vitamin E to be stopped ≥7 days before first dose if required by protocol).\n16. Pregnancy or breastfeeding at screening (positive pregnancy test). Female subjects of childbearing potential who are unwilling\u002Funable to use acceptable contraception during the study and for the duration specified in the contraceptive guidance (see protocol)are excluded.\n17. Any other clinically significant medical, psychiatric, or social condition that, in the opinion of the investigator or Medical Monitor, would compromise subject safety or protocol compliance (including inability to undergo MRI, when MRI is required for tumor assessment).",{"count":384,"type":22},20,[55],"The goal of this clinical trial is to evaluate the efficacy and safety of the MEK1\u002F2 inhibitor selumetinib in treating patients with neurofibromatosis type 2-related schwannomatosis (NF2-SWN), including both adults and children with inoperable or progressive tumors.",[359,365,364,362,363,360],[389,390],"NF2-SWN","Selumetinib",{"date":392,"type":34},"2026-07-16",{"date":170,"type":22},{"date":118,"type":22},{"name":40,"class":41},{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":23,"phases":405,"briefSummary":406,"conditions":407,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":410,"leadSponsor":412,"locationsCount":374},"100647329","phase-1-luvometinib-in-combination-with-serplulimab-for-nf2-related-tumors-100647329","NCT07708285","Luvometinib in Combination With Serplulimab for NF2-Related Tumors","A Multicenter, Open-Label Study of Luvometinib in Combination With Serplulimab for the Treatment of NF2-Related Tumors","Inclusion Criteria:\n\n1. Participants must meet the diagnostic criteria for NF2-SWN.\n2. Presence of at least one measurable target tumor, either vestibular schwannoma or meningioma, with MRI-documented volumetric progression within the past 36 months or clinical symptom progression related to the target tumor.\n3. The target tumor is considered unsuitable for surgery because of high risk.\n4. Age \\>=18 years at the time of screening.\n5. KPS \\>=70 or ECOG performance status 0 or 1.\n6. Adequate organ function based on laboratory tests obtained within 14 days before screening.\n7. Participant must be able to understand the study and voluntarily sign informed consent.\n\nExclusion Criteria:\n\n1. Pregnant, planning to become pregnant, or currently breastfeeding.\n2. Participation in another interventional clinical trial within the past 4 weeks, or radiation therapy to target lesion(s) within the past 3 years.\n3. Severe adverse reactions or intolerable toxicity from prior immune checkpoint inhibitors or MEK inhibitors.\n4. Concomitant active malignancies, uncontrolled infections, or active autoimmune diseases.\n5. Severe cardiac, hepatic, renal, gastrointestinal, or ophthalmic diseases.\n6. Any other factor that may compromise participant safety or study integrity.",{"count":404,"type":22},30,[211,55],"This is an investigator-initiated, exploratory, multicenter, open-label, single-arm clinical trial and a substudy of the Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2). The study aims to evaluate the safety, tolerability, and preliminary efficacy of luvometinib in combination with serplulimab in patients with NF2-related schwannomatosis (NF2-SWN) with progressive tumors.",[364,365,359,360,362],{"date":392,"type":34},{"date":245,"type":22},{"date":411,"type":22},"2029-12-31",{"name":40,"class":41},{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":296,"enrollmentInfo":420,"targetDuration":4,"studyType":23,"phases":422,"briefSummary":423,"conditions":424,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":42},"100626213","the-efficacy-and-safety-of-liposomal-bupivacaine-in-relieving-postoperative-pain-after-video-assisted-thoracoscopic-surgery-100626213","NCT07432711","The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Video-assisted Thoracoscopic Surgery","The Efficacy and Safety of Liposomal Bupivacaine Plus Bupivacaine Local Incisional Infiltration for Postoperative Pain in Patients Undergoing Video-assisted Thoracoscopic Surgery:A Multi-Center Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients scheduled for elective video-assisted thoracoscopic lobectomy or wedge resection under general anesthesia;\n2. Ages 18 to 64 years old；\n3. American Society of Anesthesiologists (ASA) physical status of I-III；\n4. Glasgow Coma Scale (GCS) score of 15；\n5. Patients must be able to understand the nature and potential personal consequences of the clinical trial, signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of chronic pain syndrome of any cause.\n2. Patients with heart conduction block (sinus block or atrioventricular block).\n3. Patients with unstable coronary artery disease.\n4. Patients with gastric ulcer or gastric bleeding.\n5. Patients with diabetes and are being treated with insulin.\n6. Subjects with coagulation dysfunction (prothrombin time or activated partial thromboplastin time is higher than the normal threshold) or patients who are taking oral anticoagulants for other medical reasons and have not stopped it before surgery, such as warfarin or new anticoagulants rivaroxaban or dabigatran.\n7. Patients with abnormal liver function: alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\> 2× the upper limit of normal (ULN) or total bilirubin (TBIL) ≥ 1.5×ULN.\n8. Patients with renal impairment (serum creatinine \\> 176 µmol\u002FL) or receiving dialysis treatment within 28 days before surgery.\n9. Patients with a history of diagnosed mental illness or currently taking psychotropic medication.\n10. Excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks or 3 days per week for more than 1 month), use of drugs with confirmed or suspected sedative or analgesic effects, or use of any painkiller within 24 h before surgery.\n11. Pregnancy or breastfeeding.\n12. Extreme body mass index (BMI) (\\\u003C 15 or \\> 35).\n13. Participation in another interventional trial that interferes with the intervention or outcome of this trial.\n14. Patients with a history of allergy to local anaesthetics or one of the study drugs.",{"count":421,"type":22},100,[25],"Video-assisted thoracoscopic surgery (VATS) is less invasive compared to traditional thoracotomy. It is reported that the incidence of acute pain following VATS exceeds 80%. Inadequate postoperative analgesia may trigger a series of adverse physiological stress responses, increase the occurrence of postoperative complications, and affect the rehabilitation process.If acute pain is not managed promptly and sufficiently, nearly one-quarter of patients may develop chronic pain, impacting normal life and sleep quality after discharge. Local infiltration anesthesia at the incision site is one of the simplest, safest, and most effective methods for preventing postoperative incision pain. Liposomal bupivacaine(LB) is a novel, long-acting, sustained-release amide-type local anesthetic, providing localized analgesic effects for up to 72 hours. Some researchers have reported the analgesic effects of LB VS traditional local anesthetics infiltration, but the current research results are highly heterogeneous. More prospective studies are needed to evaluate whether LB infiltration is superior to the traditional local anesthetics for the management of postoperative pain. The investigators designed this study to compare the analgesic effect of using LB plus bupivacaine for local infiltration with bupivacaine along for patients after VATS.",[425,263,426,427],"Video-assisted Thoracoscopic Surgery (VATS)","Liposomal Bupivacaine","Local Injection","2026-07-13",{"date":366,"type":34},{"date":431,"type":34},"2026-03-02",{"date":433,"type":22},"2027-06-30",{"name":40,"class":41},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":443,"enrollmentInfo":444,"targetDuration":4,"studyType":23,"phases":446,"briefSummary":447,"conditions":448,"keywords":455,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":460,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":464,"locationsCount":465},"100435326","drug-eluting-stenting-and-aggressive-medical-treatment-for-preventing-recurrent-stroke-in-intracranial-atherosclerotic-disease-trial-100435326","NCT04948749","Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial","Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial: a Prospective, Randomized, Open-labelled, Blinded End-point Trial (DREAM-PRIDE)","DREAM-PRIDE","Inclusion Criteria:\n\n1. Age from 18 to 85 years\n2. Patients with ischemic stroke within 30 days of enrolment attributed to 70% to 99% stenosis of a major intracranial artery (internal carotid artery \\[C5-C7\\], middle cerebral artery \\[M1\\], vertebral artery \\[V4\\], or basilar artery) on CTA (According to WASID method)\n3. The diameter of the target vessel between 2.0mm - 4.5mm\n4. The stenosis lesion length ≤ 14 mm\n5. Baseline modified Rankin Scale (mRS) score ≤ 3\n6. Patient understands the purpose and requirements of the study, and has provided informed consent\n\nExclusion Criteria:\n\n1. Ischemic stroke occurred within 7 days before enrolment\n2. Tandem extracranial or intracranial stenosis (70%-99%) or occlusion that is proximal or distal to the target intracranial lesion (NOTE: an exception is allowed if stenosis or occlusion involves a single vertebral artery proximal to a symptomatic basilar artery stenosis and the contralateral vertebral artery is supplying the basilar artery)\n3. Bilateral intracranial vertebral artery stenosis of 70%-99% and uncertainty about which artery is symptomatic (NOTE: an exception is that if bilateral vertebral arteries with 70%-99% stenosis but unequal in size, the dominant side is considered as symptomatic)\n4. Unilateral vertebral artery stenosis of 70%-99% with normal contralateral vertebral artery\n5. Stroke caused by perforating artery occlusion\n6. CT angiographic evidence of severe calcification at target lesion\n7. Any history of brain parenchymal or subarachnoid, subdural or extradural haemorrhage in the past 6 weeks\n8. Intracranial artery stenosis caused by non-atherosclerotic lesions, including: arterial dissection, Moyamoya disease, vasculitis disease, herpes zoster, varicella-zoster or other viral vascular diseases, neurosyphilis, any other intracranial infections, any intracranial stenosis related to cerebrospinal fluid cells, radiation-induced vascular disease, fibromuscular dysplasia, sickle cell disease, neurofibromatosis, central nervous system benign vascular disease, postpartum vascular disease, suspected vasospasm, suspicious embolism recanalization, etc\n9. History of stenting of an intracranial artery\n10. Presence of any unequivocal cardiac source of embolism\n11. Combined with intracranial tumor, aneurysm or intracranial arteriovenous malformation\n12. Cannot tolerate dual antiplatelet therapy\n13. Contraindications to heparin, rapamycin, contrast and local or general anesthesia\n14. Hemoglobin\\\u003C100g\u002FL, platelet count \\\u003C100×109\u002FL\n15. Severe hepatic and renal dysfunction\n16. INR\\>1.5 or there are uncorrectable factors leading to bleeding\n17. Major surgery within the past 30 days or planned within 90 days\n18. Renal artery, iliac artery, and coronary artery requiring simultaneous intervention\n19. Life expectancy \\\u003C1 year\n20. Pregnant or lactating women\n21. Cannot complete the follow-up due to cognitive, emotional or mental illness\n22. Other situations that are not suitable for enrolment according to the judgement of the investigator\n23. Enrolment in another study that would conflict with the current study","85 Years",{"count":445,"type":22},358,[25],"The aim of DREAM-PRIDE is to evaluate whether implantation of drug-eluting stent (DES) combined with aggressive medical treatment is more efficacious in prevention of 1-year stroke recurrence than standard medical treatment alone for symptomatic intracranial atherosclerotic disease.",[449,450,451,452,453,454],"ICAD - Intracranial Atherosclerotic Disease","ICAS - Intracranial Atherosclerosis","Drug-eluting Stent","Stroke","Drug Eluting Stents (DES)","Medical Treatment",[452,456,457,458,459,453],"Drug-eluting stent","Medical treatment","ICAD-Intracranial Atherosclerotic Disease","ICAS-Intracranial Atherosclerosis",{"date":170,"type":34},{"date":462,"type":34},"2021-07-02",{"date":147,"type":22},{"name":40,"class":41},18,{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":17,"minAge":101,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":23,"phases":474,"briefSummary":475,"conditions":476,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":480,"completionDateStruct":481,"leadSponsor":482,"locationsCount":4},"100645531","phase-2-lemborexant-use-for-cognition-improvement-in-postoperative-delirium-in-elderly-patients-a-randomized-controlled-trial-100645531","NCT07695285","Lemborexant Use for Cognition Improvement in Postoperative Delirium in Elderly Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥60 years old;\n* ASA classification I to III;\n* Patients undergoing elective surgery;\n* Sign the informed consent form.\n\nExclusion Criteria:\n\n* Tracheal intubation is expected to be retained after the operation;\n* Previous history of alcohol or drug abuse;\n* Severe abnormalities in liver and kidney functions;\n* Long-term use of sedative-hypnotic drugs;\n* Severe sleep apnea and COPD;\n* Inability to cooperate in mental state;\n* Craniocerebral surgery\n* Pregnant and lactating patients;\n* Use drugs that affect orexin metabolism.",{"count":473,"type":22},992,[55],"This prospective, randomized controlled trial aims to investigate the perioperative use of lemborexant, an orexin receptor antagonist, for reducing postoperative delirium (POD) in elderly patients undergoing general anesthesia.",[477],"Postoperative Delirium","2026-07-12",{"date":366,"type":34},{"date":116,"type":22},{"date":411,"type":22},{"name":40,"class":41},{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":17,"minAge":490,"maxAge":4,"enrollmentInfo":491,"targetDuration":493,"studyType":299,"phases":4,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":510},"100464994","china-headache-disorders-registry-100464994","NCT05334927","China HeadAche DIsorders RegiStry","CHAIRS","Inclusion Criteria:\n\n1. Age ≥ 12 years old,Any gender;\n2. The first onset age of primary headache was less than 50 years old(Age \\\u003C65 years at first diagnosis of chronic migraine);\n3. patients with primary headache (migraine, tension headache and other types of primary headache) or primary headache complicated with MOH according to ICHD-3;\n4. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. According to the ICHD-3 diagnostic criteria, there are still headaches directly related to secondary factors (except drug overuse) at the time of enrollment;\n2. Those who cannot be diagnosed as primary headache or primary headache combined with medication overuse headache according to ICHD-3;\n3. According to DSM-V diagnostic criteria, patients with severe mental diseases (such as schizophrenia, mental disorders associated with mental retardation, etc.);\n4. Patients with severe organic diseases, such as malignant tumors, and the expected survival time is less than 1 year;\n5. Pregnant,planning pregnancy or Lactating women;\n6. Subjects participating in other clinical trials;\n7. Unable to cooperate to complete the follow-up due to geographical or other reasons","12 Years",{"count":492,"type":22},10000,"1 Month","It is planned to include 10000 patients. In the China HeadAche DIsorders RegiStry CHAIRS）, patients aged over 12 years with primary headache and medication-overuse headache(MOH) were collected. The biomarkers, imaging features, cognition, genetic characteristics, ocial and demographic data, medical data, therapeutics used, and outcome of headache-related diseases were studied, and long-term follow-up was planned.",[496,497,498,499,500,501],"Headache Disorders, Primary","Migraine","New Daily Persistent Headache","Medication Overuse Headache","Tension-Type Headache","Trigeminal Autonomic Cephalalgia","2026-07-09",{"date":504,"type":34},"2026-07-10",{"date":506,"type":34},"2022-08-29",{"date":508,"type":22},"2032-12-31",{"name":40,"class":41},61,{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":517,"targetDuration":519,"studyType":299,"phases":4,"briefSummary":520,"conditions":521,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":42},"100514200","china-research-for-severe-spontaneous-intracerebral-hemorrhagecrisih-100514200","NCT05975398","China Research for Severe Spontaneous Intracerebral Hemorrhage（CRISIH）","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Spontaneous, nontraumatic intracerebral hemorrhage.\n3. Treatment with surgical or conservative management according to clinical indications and routine clinical practice.\n4. Written informed consent provided by the patient or legally authorized representative\u002Ffamily member.\n\nExclusion Criteria:\n\n1. Patients had cerebrovascular diseases associated with hemorrhage, such as intracranial aneurysm, cerebrovascular malformation, or intracranial tumors.\n2. Hemorrhagic transformation of cerebral infarction.\n3. Hemorrhage caused by cerebral venous thrombosis.\n4. Patients with severe coagulation disorder, such as hemophilia.\n5. Patients with coagulation dysfunction caused by malignant tumor, hepatic insufficiency, renal dysfunction, thrombocytopenia, coagulation diseases, or related conditions.\n6. Patients receiving other anticoagulation medications, including vitamin K antagonists or novel oral anticoagulants.\n7. Patients who died before arrival at the hospital, on arrival at the hospital, or within a short period (6 hours) after admission.",{"count":518,"type":22},2000,"1 Year","Background: Although emergency surgery may reduce mortality in patients with severe spontaneous intracerebral hemorrhage (SSICH), the effectiveness and safety of surgical treatment among SSICH patients receiving long-term oral antiplatelet therapy (LOAPT) remain unclear. The CRISIH registry was originally designed to evaluate the effect and safety of emergency surgery in SSICH patients receiving LOAPT and has subsequently continued as an ongoing multicenter registry of spontaneous intracerebral hemorrhage.\n\nMethods: The CRISIH registry is an ongoing prospective, multicenter cohort registry conducted across participating clinical centers in China. The registry was initiated in November 2019 and is designed as a 10-year registry with continued recruitment and follow-up. Data from the initial five-year enrollment period are used for interim and secondary analyses, while recruitment and follow-up continue during the subsequent registry period. Clinical, radiological, surgical, laboratory, and follow-up information are collected using standardized case report forms. For the originally registered primary outcome, patients are followed until death or 6 months after the occurrence of primary hemorrhage; selected follow-up assessments and secondary analyses may extend beyond this period according to the registry protocol.\n\nStudy Design: The CRISIH registry was designed as a prospective, multicenter cohort registry of patients with spontaneous intracerebral hemorrhage. One originally registered comparative focus evaluates SSICH patients receiving LOAPT, comparing total mortality and survival outcomes between patients receiving emergency surgical treatment and those receiving conservative treatment. The safety of surgery is assessed by comparing postoperative hemorrhagic complications among operated patients with and without LOAPT. Based on the observed clinical characteristics and outcomes of patients receiving LOAPT, the registry also evaluates ischemic events after discontinuation of LOAPT and explores coagulation function assessment strategies in operated patients receiving LOAPT.\n\nObjective: The CRISIH registry aims to prospectively evaluate clinical outcomes and management strategies in patients with spontaneous intracerebral hemorrhage. An originally registered focus of the registry is to assess the effectiveness and safety of emergency surgery among SSICH patients receiving LOAPT, thereby generating evidence to support future clinical management.\n\nSecondary Analysis Update: The present update describes an interim secondary analysis of the ongoing CRISIH registry based on patients enrolled during the initial five-year period from November 2019 to December 2024. This analysis focuses on postoperative disorders of consciousness after surgery for spontaneous intracerebral hemorrhage, with consciousness status assessed at 30, 90, 180, and 365 days after surgery using the Coma Recovery Scale-Revised. This interim secondary analysis does not alter the ongoing registry design, recruitment status, or originally registered primary outcome.",[522,523,524,525,134],"Severe Spontaneous Intracranial Hemorrhage","Long-term Antiplatelet Treatment","Emergency Surgery","Complications","2026-07-08",{"date":504,"type":34},{"date":529,"type":34},"2019-11-01",{"date":531,"type":22},"2030-12-31",{"name":40,"class":41},{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":538,"acronym":539,"eligibilityCriteria":540,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":541,"targetDuration":4,"studyType":23,"phases":543,"briefSummary":544,"conditions":545,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":550,"completionDateStruct":551,"leadSponsor":552,"locationsCount":4},"100645958","phase-1-venlafaxine-combined-with-education-and-behavioral-intervention-for-bladder-pain-syndrome-100645958","NCT07698626","Venlafaxine Combined With Education and Behavioral Intervention for Bladder Pain Syndrome","A Multicenter, Open-label, Observer-blinded Randomized Controlled Trial Comparing the Efficacy and Safety of Venlafaxine Plus Education and Behavioral Modification Program Versus Education and Behavioral Modification Program Alone in Adults With Interstitial Cystitis\u002FBladder Pain Syndrome","VEN-BPS","Inclusion Criteria:\n\nAge ≥ 18 years (all genders) Confirmed IC\u002FBPS diagnosis fulfilling AUA 2015 and ESSIC standardized diagnostic criteria, ruled out confounding urologic disorders Predominant lower urinary tract symptoms present for most days in the past 3 months Baseline bladder\u002Fpelvic pain and urinary frequency score ≥ 3 points on 0-10 Likert scale within prior 4 weeks\n\nExclusion Criteria:\n\nSymptomatic urethral stricture Active degenerative\u002Finflammatory neurological disease altering bladder\u002Fintestinal function Uncontrolled active autoimmune disease or systemic infection Medical history of pelvic tuberculosis, pelvic radiotherapy or chemotherapy-induced cystitis History of non-cutaneous malignant tumors Current diagnosis of severe psychiatric disorders (major depressive disorder, bipolar disorder, schizophrenia, psychotic disorders) Clinically significant moderate-severe cardiac, pulmonary, hepatic or renal insufficiency Documented hypersensitivity to venlafaxine or other SNRI drugs Concurrent regular use of antibiotics or NSAIDs throughout trial period Pregnancy or breastfeeding state at screening",{"count":542,"type":22},140,[211],"This study aims to compare two treatment plans for adults with bladder pain syndrome (also called interstitial cystitis), a disease that causes long-lasting bladder pain, frequent urination and urgent need to pee. All participants will receive standardized patient education and behavioral training to relieve urinary discomfort. Half of the participants will only get this behavioral intervention, while the other half will take oral venlafaxine in addition to the same behavioral training for 12 weeks. We will check patients' pain levels, urination frequency, sleep quality, mood and daily life ability at 1, 2, 6 and 12 weeks of treatment. The main goal is to see whether adding venlafaxine can better ease bladder pain and urinary symptoms without obvious side effects. This research will provide safer and more effective treatment suggestions for patients with bladder pain syndrome.",[214,546,547],"Chronic Pelvic Nociplastic Pain","Interstitial Cystitis","2026-07-07",{"date":428,"type":34},{"date":221,"type":22},{"date":223,"type":22},{"name":40,"class":41},{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":557,"acronym":4,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":559,"targetDuration":4,"studyType":23,"phases":561,"briefSummary":563,"conditions":564,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":573,"locationsCount":42},"100647025","phase-4-efficacy-and-safety-of-low-dose-blinatumomab-in-the-treatment-of-refractory-autoimmune-encephalitis-and-autoimmune-cerebellitis-100647025","NCT07686042","Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis","Inclusion Criteria:\n\n* Aged ≥18 years, male or female.\n* Confirmed diagnosis of antibody-positive autoimmune encephalitis (AE) or autoimmune cerebellitis (ACA).\n* Refractory AE\u002FACA defined as antibody-positive disease meeting all of the following:\n* Modified Rankin Scale (mRS) score \\>3 (stable for at least 24 hours) at baseline.\n* Received first-line acute therapy more than 6 weeks prior to baseline visit, defined as at least 3 days of intravenous methylprednisolone (≥500 mg\u002Fday) or equivalent oral corticosteroids, and\u002For at least 3 days of IVIG and\u002For plasma exchange (PE), or any combination thereof.\n* Received additional immunotherapy beyond the first acute course, meeting the following:\n\n  1. For rituximab: treatment initiated at least 2 months prior to screening, last dose at least 4 weeks prior to baseline, and no improvement in mRS score for 2 months before baseline.\n  2. For other immunosuppressive therapies (IST; e.g., mycophenolate mofetil, cyclophosphamide, azathioprine): treatment for at least 2 months prior to screening, stable dose for at least 4 weeks prior to baseline, and no improvement in mRS score for 4 weeks before baseline.\n  3. For oral corticosteroids: stable dose \\>20 mg\u002Fday prednisone equivalent, no dose increase for 4 weeks prior to baseline, and no improvement in mRS score for 4 weeks before baseline.\n  4. For repeated first-line therapy courses: completed at least 2 weeks prior to baseline visit.\n* For patients on oral corticosteroids: stable dose ≥20 mg\u002Fday prednisone equivalent, no dose increase for 4 weeks prior to enrollment, and no improvement in mRS score for 4 weeks before enrollment.\n* For patients on rituximab: treatment initiated at least 2 months prior to enrollment, last dose at least 4 weeks prior to enrollment, and no improvement in mRS score for 4 weeks before enrollment.\n* For patients on other IST (e.g., azathioprine, mycophenolate mofetil): treatment for at least 2 months prior to enrollment, stable dose for at least 4 weeks prior to enrollment, and no improvement in mRS score for 4 weeks before enrollment.\n* For patients on repeated first-line therapy courses: completed at least 2 weeks prior to enrollment.\n* Patient or legally authorized representative provides written informed consent.\n* For females of childbearing potential: agreement to abstain from heterosexual intercourse or use adequate contraception during treatment and for at least 3 months after the last dose. Post-menopausal females (≥12 consecutive months of amenorrhea without other cause) or those permanently sterilized by surgery (e.g., bilateral oophorectomy, hysterectomy) are not considered of childbearing potential. Acceptable contraceptive methods include bilateral tubal ligation, male sterilization, hormonal contraceptives, hormonal IUDs, copper IUDs, male\u002Ffemale condoms with spermicide, and contraceptive diaphragms\u002Fcaps with spermicide. Periodic abstinence and withdrawal are not considered adequate.\n\nDiagnostic Criteria for Antibody-Positive Autoimmune Encephalitis (AE):\n\nA. Clinical presentation: Acute or subacute onset (\\\u003C3 months) with ≥1 neuropsychiatric symptom:\n\n1. Limbic encephalitis: memory impairment, seizures, psychiatric symptoms.\n2. Encephalopathy syndrome: diffuse or multifocal brain dysfunction.\n3. CSF pleocytosis (\\>5×10⁶\u002FL), lymphocytic inflammation, or oligoclonal bands.\n\nB. Investigations: ≥1 of the following or associated tumors:\n\n1. CSF abnormalities as above.\n2. Neuroimaging\u002FEEG: MRI T2\u002FFLAIR hyperintensity in limbic system or other regions (excluding non-specific white matter changes\u002Fstroke); PET hypermetabolism in limbic system or multifocal cortex\u002Fbasal ganglia; EEG with focal epileptiform discharges or diffuse\u002Fmultifocal slowing.\n3. Specific tumors associated with AE. C. Confirmatory test: Positive anti-neuronal antibodies. D. Other causes excluded. All criteria A-D must be met.\n\nDiagnostic Criteria for Autoimmune Cerebellitis (ACA):\n\n1. Acute or subacute onset with predominant cerebellar syndrome.\n2. No significant cerebellar\u002Fbrainstem atrophy on brain MRI within 3 months of onset.\n3. Meets either 3.1 or 3.2:\n\n   3.1 Positive anti-cerebellar antibodies in serum and\u002For CSF detected by cell-based assay (CBA).\n\n   3.2 At least two of the following: personal or first-degree family history of autoimmune disease; CSF pleocytosis (\\>5×10⁶\u002FL) or oligoclonal bands; characteristic immunofluorescence pattern of anti-Purkinje cell antibodies on tissue-based assay (TBA); presence of systemic autoimmune disease-related antibodies.\n4. Other causes excluded.\n\nExclusion Criteria:\n\n* Systemic or central nervous system tumors (e.g., gliomatosis cerebri), history of cancer (excluding ovarian\u002Fextra-ovarian teratoma, skin squamous cell carcinoma, or basal cell carcinoma with documented cure ≥3 months prior to enrollment); hereditary diseases (e.g., mitochondrial encephalopathy); neurodegenerative diseases (e.g., Lewy body dementia); prior epilepsy with ongoing seizures; severe traumatic brain injury; metabolic\u002Ftoxic encephalopathy (e.g., Wernicke encephalopathy).\n* Infectious diseases (e.g., viral encephalitis); active or uncontrolled infection requiring systemic treatment within 1 week prior to screening; history of severe recurrent or chronic infections, especially respiratory infections.\n* Positive hepatitis B surface antigen\u002F核心 antigen and\u002For positive hepatitis C PCR at screening.\n* Active tuberculosis at screening.\n* Diseases requiring long-term corticosteroid or immunosuppressive therapy.\n* Known history of primary immunodeficiency (congenital or acquired) or conditions predisposing to infection (e.g., HIV infection, splenectomy).\n* History of solid organ or hematopoietic stem cell transplantation within 3 months prior to screening.\n* Live or attenuated vaccine within 3 weeks prior to enrollment (inactivated vaccines are allowed); BCG vaccine within 1 year prior to enrollment.\n* Congenital heart disease, acute myocardial infarction within 6 months prior to screening, severe arrhythmias (e.g., polymorphic ventricular tachycardia), moderate to large pericardial effusion, severe myocarditis, hemodynamic instability requiring vasopressors, left ventricular ejection fraction (LVEF) ≤55%, or significant ECG abnormalities.\n* Any of the following laboratory abnormalities:\n* Absolute lymphocyte count (ALC) ≤0.5×10⁹\u002FL\n* Absolute neutrophil count (ANC) ≤0.5×10⁹\u002FL\n* Immunoglobulin G (IgG) ≤5.0 g\u002FL\n* CD4 T-cell count \\\u003C300 cells\u002FµL\n* Hemoglobin ≤80 g\u002FL\n* Platelet count ≤75×10⁹\u002FL\n* Estimated glomerular filtration rate (eGFR) ≤30 mL\u002Fmin\u002F1.73m²\n* AST\u002FALT ≥3× upper limit of normal (ULN); total bilirubin ≥2×ULN\n* Pregnant or breastfeeding females, or those planning pregnancy during the trial.\n* Incomplete medical records or refusal to participate in the registry.\n* Known allergy or hypersensitivity to any component of the study drug or to any biologic therapy.",{"count":560,"type":22},12,[562],"PHASE4","This is a multicenter, single-arm, continuous, prospective, interventional registry study designed to systematically evaluate the efficacy and safety of low-dose blinatumomab in patients with antibody-mediated refractory autoimmune encephalitis (AE) and autoimmune cerebellitis. Eligible participants will be patients with a confirmed diagnosis of refractory AE or autoimmune cerebellitis who have provided written informed consent. All enrolled patients will receive blinatumomab treatment according to a unified protocol, consisting of two cycles:\n\nCycle 1 (Week 1): Continuous intravenous infusion at 9 µg\u002Fday for 5 consecutive days (total dose: 45 µg).\n\nCycle 2 (Week 3): Continuous intravenous infusion at 9 µg\u002Fday for 5 consecutive days (total dose: 45 µg). If there is no improvement in the modified Rankin Scale (mRS) score at Week 3 and the proportion of peripheral blood B cells (CD3-\u002FCD19+) remains \\>1%, the dose may be optimized to 15 µg\u002Fm²\u002Fday (maximum 28 µg\u002Fday).\n\nDuring the study, all patients will undergo regular follow-up visits to collect data on clinical symptoms, functional scores, immunological biomarkers, and adverse events, to comprehensively assess the efficacy and safety of the treatment. This study uses a non-randomized, open-label design with no blinding or control group.",[565,566],"Autoimmune Encephalitis (AE)","Autoimmune Cerebellitis","2026-07-02",{"date":569,"type":34},"2026-07-06",{"date":571,"type":22},"2026-06-24",{"date":118,"type":22},{"name":40,"class":41},{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":582,"targetDuration":4,"studyType":23,"phases":584,"briefSummary":585,"conditions":586,"keywords":588,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":600,"locationsCount":601},"100633461","phase-3-efficacy-and-safety-of-minocycline-in-patients-with-acute-ischaemic-stroke-receiving-intravenous-thrombolysis-100633461","NCT07526987","Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis","Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis (EMPHASIS-2): A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Trial","EMPHASIS-2","Inclusion Criteria:\n\n1. Age between 18 and 80 years;\n2. Patients with acute ischaemic stroke confirmed by CT or MRI;\n3. Having received or planning to receive intravenous thrombolysis within 4.5 hours of onset or within an extended window of 4.5-24 hours based on guideline recommendations (The intravenous thrombolytic drugs include: alteplase, tenecteplase, reteplase or recombinant human prourokinase);\n4. The study drug can be applied before intravenous thrombolysis or within 2 hours after the initiation of intravenous thrombolysis;\n5. 6≤NIHSS≤25, and Ia≤1;\n6. Signed informed consent.\n\nExclusion Criteria:\n\n1. mRS score ≥ 2 prior to onset of the current stroke;\n2. History of pseudomembranous colitis or antibiotic-associated colitis;\n3. Known allergy or intolerance to tetracycline antibiotics or any component of minocycline;\n4. Known resistance to other tetracyclines;\n5. Use of tetracycline antibiotics within the past 7 days;\n6. Presence of a known community-acquired bacterial infection (e.g., pneumonia, urinary tract infection) or any other concurrent infection requiring antibiotic treatment;\n7. History of intracranial hemorrhagic disease within the past 3 months, for example, parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural or epidural hematoma.\n8. Malformation, tumor, abscess, or other major non-ischaemic brain diseases (e.g., multiple sclerosis, other intracranial space-occupying lesions) on baseline cranial CT or MRI;\n9. Rare or unknown etiology of large vessel occlusion (e.g., arterial dissection, vasculitis);\n10. History of systemic lupus erythematosus;\n11. Known severe hepatic insufficiency (ALT or AST \\> 3 times of the upper limit of normal), severe renal insufficiency (creatinine \\> 3.0 mg\u002FdL \\[265.2 μmol\u002FL\\], estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73m², or have received dialysis before randomization);\n12. Use of tretinoin, androgen or antiandrogen treatment (e.g., anabolic steroids, spironolactone) within the past 3 months;\n13. Pregnant, breastfeeding, or of childbearing potential who are unwilling to use effective contraception throughout the study;\n14. Presence of a severe non-cardio-cerebrovascular disease with a life expectancy of less than 6 months;\n15. Participation in any other clinical trial within the past 30 days;\n16. Any other condition that is not suitable for participating in this clinical trial, such as inability to understand or follow the study procedures due to physical, cognitive, emotional, or mental disorders.",{"count":583,"type":22},934,[83],"The aim of this study is to assess the efficacy and safety of minocycline in improving functional outcome among patients with acute ischaemic stroke receiving intravenous thrombolysis.",[587],"Ischaemic Stroke",[589,590,591,592,593],"Ischaemic stroke","Intravenous thrombolysis","Minocycline","Randomized Controlled Trial","Functional outcome","2026-06-30",{"date":596,"type":34},"2026-07-01",{"date":598,"type":34},"2026-06-05",{"date":118,"type":22},{"name":40,"class":41},3,""]